Clinical Trials Logo

Thyroid Neoplasm clinical trials

View clinical trials related to Thyroid Neoplasm.

Filter by:

NCT ID: NCT01617694 Completed - Thyroid Neoplasm Clinical Trials

Comparison Between Remifentanil Target-controlled Infusion and Dexmedetomidine Bolus Administration for Smooth Emergence From General Sevoflurane Anesthesia

Start date: June 2011
Phase: N/A
Study type: Interventional

Remifentanil target-controlled infusion and dexmedetomidine single-dose administration are known to reduce airway response and haemodynamic stimulation during anaesthetic recovery. The investigators will compare the effects of two drugs on prevention of cough during emergence from general sevoflurane anaesthesia.

NCT ID: NCT01308320 Completed - Thyroid Neoplasm Clinical Trials

Dose-dependent Effect of Fentanyl on Cough Attenuation During Emergence From General Anaesthesia

Start date: February 2010
Phase: Phase 4
Study type: Interventional

Fentanyl is expected to suppress tracheal tube-induced cough during emergence from general anaesthesia through binding to its receptors in the brainstem. However, it has not been proven if fentanyl has a complication-free, dose-dependent effect on cough suppression during emergence from sevoflurane anaesthesia. The purpose of this study is to evaluate the relationship between fentanyl doses and cough suppression during emergence from sevoflurane anaesthesia.

NCT ID: NCT01226914 Completed - Goiter Clinical Trials

A Trial Comparing Wound Drainage and Post-operative Complications With and Without the Use of EVICEL™ Fibrin Sealant in Thyroidectomy

Start date: June 2010
Phase: N/A
Study type: Interventional

Primary Objectives - To compare the amount of post-operative wound drainage between the group of patients in which EVICEL™ spray is utilized (Arm A), and the group of patients in which an EVICEL™ placebo is utilized (Arm B). - To compare the length of time to drain removal between Arm A and Arm B. Secondary objectives - To compare the incident or rates of seroma, hematoma, and post-operative edema between the two groups. - To compare the reported pain experienced in each group at selected time points using a standard numerical rating scale (NRS). - To compare the length of hospital stay between the two groups of patients.

NCT ID: NCT01182285 Completed - Thyroid Neoplasm Clinical Trials

A Phase II Trial of Valproic Acid in Patients With Advanced Thyroid Cancers of Follicular Cell Origin

Start date: September 24, 2010
Phase: Phase 2
Study type: Interventional

Background: - Patients who have advanced thyroid cancer have a low long-term survival rate. These types of thyroid cancer do not respond well to conventional surgery or radiation, or to specific thyroid cancer treatments such as radioactive iodine treatment and thyroid hormone for thyroid stimulating hormone (TSH) suppression. - Valproic acid has long been approved as an anticonvulsant to treat seizures in patients with epilepsy. It has also been used to treat bipolar disorder. Recent studies have shown that valproic acid has promising effects in thyroid cancer treatment because it may help destroy cancer cells and help conventional treatments be more effective. However, valproic acid is not approved for thyroid cancer and is therefore an investigational drug. Objectives: - To determine whether valproic acid can inhibit tumor growth or induce tumor cell death. - To determine whether valproic acid can make tumor cells increase their uptake of radioiodine. Eligibility: - Individuals at least 18 years of age who have advanced-stage thyroid cancer that is either unresponsive to conventional treatments or fails to absorb radioiodine. Design: - Eligible participants will continue on the standard thyroid hormone suppression therapy and begin receiving valproic acid for a total of 10 weeks. Participants will keep a study diary to record doses and side effects, and will have regular clinic visits to provide blood samples and receive additional valproic acid. - After 10 weeks, participants will have a Thyrogen scan to measure radioiodine uptake after valproic acid therapy. Tumor biopsies and blood samples will be taken at this time. - If there is increased radioiodine uptake on the scan, participants will have additional radioiodine therapy. - If there is no increased uptake on the scan, participants will continue on valproic acid for 7 more weeks. After 16 total weeks of treatment, additional blood samples and scans will be taken. Participants may continue to take valproic acid if the thyroid cancer appears to be responding to the treatment. - Follow-up visits will be scheduled at 3, 6, 9 (for patients continuing on valproic acid only), and 12 months.

NCT ID: NCT01137097 Completed - Thyroid Neoplasm Clinical Trials

Lateral Neck Sentinel Lymph Node Biopsy(LSLNB)in PTC

LSLNB
Start date: June 2009
Phase: Phase 2/Phase 3
Study type: Interventional

Objective: To investigate the incidence of lateral neck node occult metastasis and to show the usefulness of sentinel lymph node biopsy (SLNB) in the detection of lateral neck node metastasis in thyroid carcinoma, the investigators used a radioisotope to detect the sentinel lymph node. Summary Background Data: Although occult lymph node metastasis to the lateral neck compartment is common in papillary thyroid carcinoma, the incidence and patterns of lateral neck node metastasis in papillary carcinoma are not known.

NCT ID: NCT01103557 Completed - Thyroid Neoplasm Clinical Trials

Prophylactic Selective Lateral Neck Dissection in Patients With Papillary Thyroid Carcinoma

Start date: n/a
Phase: N/A
Study type: Interventional

The purpose of this study is to prospectively analyze the incidence of occult lateral neck metastasis (LNM) and to elucidate the factors that predict LNM in papillary thyroid carcinoma (PTC) with central neck metastasis (CNM) by performing prophylactic selective lateral neck dissection (SND).

NCT ID: NCT00647140 Terminated - Thyroid Carcinoma Clinical Trials

Clinical Evaluation of 18F-DOPA Positron Emission Tomography in Medullary Thyroid Cancer

DOPMET
Start date: August 2007
Phase: Phase 2
Study type: Interventional

Medullary thyroid carcinoma (MTC) is a rare tumor arising from C cells of the thyroid gland and belonging to the endocrine tumors. 18F-DOPA PET, based on tha capacity of endocrine tumor cells to take-up, decarboxylate and store amino-acids, such 3-4-dihydroxyphenylalanine(DOPA), is used for imaging endocrine tumors. The aim of the study was to evaluate the contribution of 18F-DOPA whole-body PET for the detection of recurrences in patients with proven recurrent MTC without evidence of recurrence or metastases on several imaging modalities.

NCT ID: NCT00385983 Not yet recruiting - Thyroid Nodule Clinical Trials

Total Thyroidectomy With Harmonic Scalpel®

Start date: n/a
Phase: Phase 4
Study type: Interventional

Harmonic scalpel is a new surgical instrument. Its use has been recommended in patients submitted to total thyroidectomy. Few randomized controlled trials has been published. However they had small sample sizes, used intermediate outcomes and included different surgical procedures. Our objective is to asses the use of Harmonic scalpel in patients submitted to total thyroidectomy using surgical complications, operative time, drainage volume, postoperative pain, length of stay and costs as outcomes. Our hypothesis is that Harmonic scalpel decreases operative time,drainage volume, postoperative pain, length of stay and costs without increasing surgical complications